<?xml version="1.0" encoding="UTF-8"?>
<p>Both SARS-CoV and SARS-CoV-2 use angiotensin converting enzyme II (ACE2) to enter human and bat cells [
 <xref rid="B18-ijms-21-05559" ref-type="bibr">18</xref>]. The interaction between glutamine 493 in the RBD region of the SARS-CoV-2 spike protein and lysine 31 on the human ACE2 receptor plays an important role in viral binding and entry [
 <xref rid="B19-ijms-21-05559" ref-type="bibr">19</xref>]. Cryo-electron microscopy (Cryo-EM) structure analysis of the spikes shows that the binding efficiency of the SARS-CoV-2 S protein to ACE2 is 10 to 20-fold higher than for SARS-CoV [
 <xref rid="B20-ijms-21-05559" ref-type="bibr">20</xref>]. A single N501T mutation in the spike protein of SARS-CoV-2 significantly enhances the binding affinity for its receptor, contributing to the high transmissibility of COVID-19 [
 <xref rid="B19-ijms-21-05559" ref-type="bibr">19</xref>].
</p>
